Press Release
Xintela AB (publ)
556780-3480
2016-12-22 16:00

XINTELA REPORTS POSITIVE RESULTS FROM COMPLETED HORSE STUDY

Lund, Sweden, 22 December 2016 – Xintela AB (publ), announces today that the company's completed horse study met its primary endpoint, demonstrating that Xintela's stem cells are safe. Xintela can now take the next step in the development of an effective, safe stem cell product for the treatment of cartilage damage and osteoarthritis.

"We are very pleased to report a positive outcome from the horse study. The results give us confidence to take the next step in the development of a horse stem cell product, a clinical efficacy study on horses with osteoarthritis", says Xintela's CEO, Evy Lundgren-Åkerlund.

Xintela's horse study, carried out under GLP (Good Laboratory Practice) at Cornell University in Ithaca, New York, demonstrated that Xintela's stem cells are safe and did not cause pain or other adverse events. Furthermore, the cells did not lead to any unwanted tissue changes such as ectopic bone formation. In addition, the study results indicate that Xintela's stem cells have a protective effect on the joint, which is now being further evaluated in collaboration with Dr Lisa Fortier at Cornell University.

"The results are also very important in our efforts to obtain regulatory approval to support clinical trials in humans," says Evy Lundgren-Åkerlund.

About the horse study

Xintela's stem cells, isolated from a donor horse and selected using the company's integrin marker technology, were injected into the hind leg joint, corresponding to the human ankle. The joint of the other hind leg was injected with a salt solution as a control.

The horses in the study had a type of cartilage damage that mimics post-traumatic osteoarthritis. Upon completion of the six-month study, all tissues in the joint, including cartilage, underwent in-depth analysis including MRI scanning and histology. Several other organs were also examined for any unwanted effects of the injected stem cells.

About osteoarthritis

Osteoarthritis is a chronic joint disease that involves a gradual degeneration of the cartilage which is debilitating and often very painful. It is estimated that 630 million people worldwide suffer from osteoarthritis. Cartilage damage and osteoarthritis in horses is also very common. Today, there is no disease modifying treatment available for osteoarthritis.

The total global market for osteoarthritis therapy is expected to grow from the current $ 3.6 billion (2014) to $ 9.2 billion (2024).

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel:+46 70-329 18 71
E-mail: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

Queries regarding trading with Xintela shares and warrants will be answered by the company's Certified Adviser, Erik Penser Bank AB. Telephone: +46 8-463 80 00.

Press Release
Xintela AB (publ)
556780-3480
2016-12-22 16:00

Media and Investor Relations related queries should be directed to:
Mårten Svanberg, Laika Consulting
Tel: +46 70-362 70 05
E-mail: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 22 December 2016, at 4:00 p.m CET.